Janus Henderson Group PLC Has $642.54 Million Holdings in Stryker Co. (NYSE:SYK)

Janus Henderson Group PLC cut its stake in Stryker Co. (NYSE:SYK) by 9.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,784,584 shares of the medical technology company’s stock after selling 185,173 shares during the period. Janus Henderson Group PLC owned 0.47% of Stryker worth $642,544,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of SYK. Principal Financial Group Inc. boosted its stake in shares of Stryker by 6.2% in the 3rd quarter. Principal Financial Group Inc. now owns 398,422 shares of the medical technology company’s stock valued at $143,934,000 after purchasing an additional 23,329 shares during the last quarter. ST Germain D J Co. Inc. boosted its stake in Stryker by 14.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 2,362 shares of the medical technology company’s stock valued at $850,000 after acquiring an additional 300 shares during the last quarter. Sugarloaf Wealth Management LLC grew its holdings in Stryker by 11.2% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 496 shares of the medical technology company’s stock worth $179,000 after acquiring an additional 50 shares during the period. Czech National Bank raised its position in shares of Stryker by 6.6% during the 4th quarter. Czech National Bank now owns 74,430 shares of the medical technology company’s stock valued at $26,799,000 after acquiring an additional 4,587 shares during the last quarter. Finally, Clark & Stuart Inc acquired a new position in shares of Stryker in the 4th quarter valued at $5,348,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Canaccord Genuity Group upped their price objective on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Evercore ISI cut their price target on shares of Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 target price on Stryker in a research note on Tuesday, March 4th. Finally, Barclays lifted their price objective on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $427.05.

Stryker Trading Down 0.4 %

Shares of SYK stock opened at $380.87 on Friday. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a market capitalization of $145.37 billion, a PE ratio of 49.08, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The firm has a 50 day moving average price of $365.47 and a two-hundred day moving average price of $374.38. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.50 EPS. As a group, analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s dividend payout ratio is 45.41%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. This represents a 5.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.